Department of Biotechnology, Asia University, Taichung 41354, Taiwan.
Curr Opin Pharmacol. 2011 Aug;11(4):301-7. doi: 10.1016/j.coph.2011.03.005. Epub 2011 Apr 12.
FK506-binding proteins (FKBPs) are intracellular receptors for FK506 and rapamycin, immunosuppressants that have recently been utilized as anticancer drugs. In the cytoplasm, FKBPs and these drugs modulate signal transduction pathways. However, recent reports reveal novel functions of FKBPs in the nucleus, which include regulation of transcription factors, histone chaperone activity, and modifications of chromatin structure. These activities are known to affect gene expression, DNA repair, and DNA replication. Therefore, elucidation of the nuclear functions of FKBPs will help researchers and clinicians better understand how immunosuppressants work as anticancer drugs, which might in turn lead to novel designs of cancer therapy.
FK506 结合蛋白(FKBPs)是 FK506 和雷帕霉素的细胞内受体,这两种免疫抑制剂最近已被用作抗癌药物。在细胞质中,FKBP 与这些药物共同调节信号转导途径。然而,最近的研究报告揭示了 FKBPs 在核内的新功能,包括调节转录因子、组蛋白伴侣活性以及染色质结构的修饰。这些活性已知会影响基因表达、DNA 修复和 DNA 复制。因此,阐明 FKBPs 的核功能将有助于研究人员和临床医生更好地理解免疫抑制剂作为抗癌药物的作用机制,这可能反过来导致癌症治疗的新设计。